155 related articles for article (PubMed ID: 28683085)
1. An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII.
Pezeshkpoor B; Schreck U; Biswas A; Driesen J; Berkemeier AC; Pavlova A; Müller J; Oldenburg J
PLoS One; 2017; 12(7):e0180456. PubMed ID: 28683085
[TBL] [Abstract][Full Text] [Related]
2. P3-P3' residues flanking scissile bonds in factor VIII modulate rates of substrate cleavage and procofactor activation by thrombin.
Newell-Caito JL; Griffiths AE; Fay PJ
Biochemistry; 2012 Apr; 51(16):3451-9. PubMed ID: 22455313
[TBL] [Abstract][Full Text] [Related]
3. Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function.
DeAngelis JP; Wakabayashi H; Fay PJ
J Biol Chem; 2012 May; 287(19):15409-17. PubMed ID: 22411993
[TBL] [Abstract][Full Text] [Related]
4. Acidic Region Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg1689.
Nakajima Y; Minami H; Nogami K
Thromb Haemost; 2021 Oct; 121(10):1274-1288. PubMed ID: 33592631
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis at Arg740 facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII.
Newell JL; Fay PJ
J Biol Chem; 2007 Aug; 282(35):25367-75. PubMed ID: 17595160
[TBL] [Abstract][Full Text] [Related]
6. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
Pezeshkpoor B; Gazorpak M; Berkemeier AC; Singer H; Pavlova A; Biswas A; Oldenburg J
Ann Hematol; 2019 Aug; 98(8):1855-1865. PubMed ID: 30997536
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for the activation of human factor VIII by thrombin.
Myles T; Yun TH; Leung LL
Blood; 2002 Oct; 100(8):2820-6. PubMed ID: 12351390
[TBL] [Abstract][Full Text] [Related]
8. Amino acid residues 721-729 are required for full factor VIII activity.
Kjalke M; Heding A; Talbo G; Persson E; Thomsen J; Ezban M
Eur J Biochem; 1995 Dec; 234(3):773-9. PubMed ID: 8575434
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.
De Cristofaro R; De Filippis V
Biochem J; 2003 Jul; 373(Pt 2):593-601. PubMed ID: 12689334
[TBL] [Abstract][Full Text] [Related]
10. Cleavage at Arg-1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII.
Newell JL; Fay PJ
J Biol Chem; 2009 Apr; 284(17):11080-9. PubMed ID: 19240027
[TBL] [Abstract][Full Text] [Related]
11. Residues flanking scissile bonds in Factor VIII modulate rates of cleavage and proteolytic activation catalyzed by Factor Xa.
Griffiths AE; Wintermute J; Newell-Caito JL; Fay PJ
Biochemistry; 2013 Nov; 52(45):8060-8. PubMed ID: 24128092
[TBL] [Abstract][Full Text] [Related]
12. The role of P4-P3' residues flanking Arg336 in facilitating activated protein C-catalyzed cleavage and inactivation of factor VIIIa.
DeAngelis JP; Varfaj F; Wakabayashi H; Fay PJ
Thromb Res; 2011 Nov; 128(5):470-6. PubMed ID: 21470668
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
Johnson DJ; Pemberton S; Acquila M; Mori PG; Tuddenham EG; O'Brien DP
Thromb Haemost; 1994 Apr; 71(4):428-33. PubMed ID: 8052958
[TBL] [Abstract][Full Text] [Related]
14. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
Shima M; Ware J; Yoshioka A; Fukui H; Fulcher CA
Blood; 1989 Oct; 74(5):1612-7. PubMed ID: 2506948
[TBL] [Abstract][Full Text] [Related]
15. Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII.
Newell JL; Fay PJ
Biochemistry; 2008 Aug; 47(33):8786-95. PubMed ID: 18642885
[TBL] [Abstract][Full Text] [Related]
16. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.
Takeyama M; Wakabayashi H; Fay PJ
Thromb Haemost; 2013 Feb; 109(2):187-98. PubMed ID: 23224054
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
[TBL] [Abstract][Full Text] [Related]
18. The extended cleavage specificity of human thrombin.
Gallwitz M; Enoksson M; Thorpe M; Hellman L
PLoS One; 2012; 7(2):e31756. PubMed ID: 22384068
[TBL] [Abstract][Full Text] [Related]
19. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
[TBL] [Abstract][Full Text] [Related]
20. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
